Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? The ...

The ETF industry has long been dominated by products based on market cap ... about 8.64% of the fund's total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Gilead Sciences Inc (GILD).

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise ...

Vertex Pharmaceuticals continues to develop therapies ... There is more to like as well. Vertex'w newest products fit the company's MO. Casgevy, approved in 2023, is a medicine for two rare ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain treatment that could be a game-changer for both patients and the company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.